Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

Abstract Background In the initial absence of specific reversal agents for factor Xa inhibitors (FXa‐Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical...

Full description

Bibliographic Details
Main Authors: Roisin Bavalia, Rahat Abdoellakhan, Herm Jan M. Brinkman, Marjolein P. A. Brekelmans, Eva N. Hamulyák, Marleen Zuurveld, Barbara A. Hutten, Peter E. Westerweel, Renske H. Olie, Hugo ten Cate, Marieke Kruip, Saskia Middeldorp, Karina Meijer, Michiel Coppens
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
dabigatran
emergencies
factor Xa inhibitors
hemorrhage
idarucizumab
prothrombin complex concentrates
Online Access:https://doi.org/10.1002/rth2.12336

Internet

https://doi.org/10.1002/rth2.12336

Similar Items